Bristol Myers Squibb (BMY) Invested Capital (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Invested Capital data on file, last reported at $64.2 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $64.2 billion, up 28.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.2 billion (up 28.94% YoY), and the FY2025 annual result was $63.3 billion, down 1.62% from the prior year.
• Invested Capital grew to $64.2 billion in Q1 2026 per BMY's latest filing, from $63.3 billion in the prior quarter.
• Over five years, Invested Capital peaked at $67.3 billion in Q3 2025 and troughed at -$2.6 billion in Q2 2023.
• A 5-year average of $43.2 billion and a median of $49.0 billion in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2024: Invested Capital tumbled 140.4% in 2023, then jumped 2101.61% in 2024.
• A 5-year view of Invested Capital shows it stood at $37.7 billion in 2022, then advanced by 0.82% to $38.0 billion in 2023, then surged by 69.41% to $64.3 billion in 2024, then fell by 1.62% to $63.3 billion in 2025, then advanced by 1.43% to $64.2 billion in 2026.
• Business Quant data shows BMY's Invested Capital at $64.2 billion in Q1 2026, $63.3 billion in Q4 2025, and $67.3 billion in Q3 2025.